The Epic Sciences team attended the ASCO Genitourinary Cancer Symposiums Annual Meeting in San Francisco, CA from February 14 - 16, 2019.
Thursday, February 14th - 11:30 AM-1:00 PM and 5:30 PM–6:30 PM
Poster Session A: Prostate Cancer and Trials in Progress.
Board K4 - Morphology-predicted, large-scale transition (LST) number in circulating tumor cells (CTC) as a biomarker of chromosomal instability (CIN) to assess early resistance to standard of care (SOC) drugs in mCRPC.
Authors: Howard Scher, MD, FASCO et al.
Board N4 - A phase II trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or BRCA defects.
Authors: Simon Chowdhury, MD, PhD et al.
Friday, February 15th - 12:15 PM-1:45 PM and 5:15 PM–6:15 PM
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, Testicular, and Adrenal Cancers.
Board F14 - Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi).
Authors: Zishuo Hu et al.
Authors: Vadim Koshkin, MD et al.